Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Row over Lancet alert on Crestor

GPs have been urged by The Lancet to think twice before prescribing the statin Crestor (rosuvastatin). The accusation that manufacturer Astra-Zeneca 'forced' Crestor into the market despite there being 'no reliable data about efficacy and safety' has drawn a furious response from the company.

The Lancet said: 'Doctors should pause before prescribing this drug and tell patients the truth ­ that, compared with its competitors, rosuvastatin has an inferior evidence base supporting its safe use.'

But AstraZeneca chief executive Sir Tom McKillop said Crestor had been subject to clinical trials in more than 10,000 patients and had been approved by over 30 regulatory bodies. He said the drug's profile ­ with 80 per cent of patients on 10mg reaching LDL cholesterol goals and increasing their HDL cholesterol ­ was 'unmatched'.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say